Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nanjing China-Australia Institute Of Translational Medicine Co. Ltd. is currently managing a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action at this time. This single matter suggests a focused prosecution effort within this specific technical field. The presence of a single pending action allows for a concentrated legal strategy regarding this particular asset. Practitioners should note that this filing represents the current active engagement for the company with the patent office.
The prosecution of this portfolio involves 1 distinct examiner and 1 distinct art unit. This concentration indicates that the company's current patent activity is confined to a specific niche within the Biotechnology & Pharmaceuticals sector. Because the work is limited to a single art unit, the prosecution process is subject to the specific internal practices and timelines of that individual unit. Having a single distinct examiner simplifies the communication process but also means that the success of the portfolio is dependent on the perspective of that specific individual.
WHITE, DAWANNA SHAR-DAY is the busiest examiner associated with this portfolio. This individual is responsible for 1 pending office action. Since the busiest examiner is the person handling the pending work, the outcome of the current prosecution depends on the interactions with this person. Practitioners should focus on the specific examination history of WHITE, DAWANNA SHAR-DAY to anticipate potential challenges or opportunities.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18817895 | PYRIDONE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE | WHITE, DAWANNA SHAR-DAY | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18817895 | PYRIDONE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE | WHITE, DAWANNA SHAR-DAY | 1627 | §112 | Non-Final OA | — | Pending | Aug 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNanjing China-Australia Institute Of Translational Medicine Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dawanna Shar-Day White has the most, with 1 of Nanjing China-Australia Institute Of Translational Medicine Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
